Cassia Cearley Biography and Net Worth
Cassia Cearley, Ph.D. is the Chief Business Officer (CBO) of Icosavax. Cassia has worked with pharmaceutical companies in various roles for more than 10 years. Prior to joining Icosavax, Cassia was the vice president of research for Aptinyx Inc., where she led a team responsible for building a portfolio of small molecule NMDA receptor modulators. Prior to this, Cassia was on the corporate development team of Naurex Inc, which was responsible for the spinout of Aptinyx Inc. and the sale of Naurex to Allergan. Previously, Cassia worked at Takeda Pharmaceuticals, where she was the director of portfolio management. Prior to Takeda, Cassia was an engagement manager with the life sciences practice of L.E.K. Consulting. Cassia received a Ph.D. in neuroscience from University of Pennsylvania and a B.S. in neuroscience from the Washington State University Honors College.
What is Cassia Cearley's net worth?
The estimated net worth of Cassia Cearley is at least $1.42 million as of May 23rd, 2023. Dr. Cearley owns 141,847 shares of Icosavax stock worth more than $1,419,888 as of June 7th. This net worth evaluation does not reflect any other investments that Dr. Cearley may own. Learn More about Cassia Cearley's net worth.
How do I contact Cassia Cearley?
Has Cassia Cearley been buying or selling shares of Icosavax?
During the last quarter, Cassia Cearley has sold $100,000.00 in shares of Icosavax stock. Most recently, Cassia Cearley sold 10,000 shares of the business's stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $10.00, for a transaction totalling $100,000.00. Following the completion of the sale, the insider now directly owns 141,847 shares of the company's stock, valued at $1,418,470. Learn More on Cassia Cearley's trading history.
Are insiders buying or selling shares of Icosavax?
During the last year, insiders at the sold shares 18 times. They sold a total of 164,226 shares worth more than $1,428,671.79. The most recent insider tranaction occured on May, 23rd when insider Cassia Cearley sold 10,000 shares worth more than $100,000.00. Insiders at Icosavax own 39.1% of the company. Learn More about insider trades at Icosavax.
Information on this page was last updated on 5/23/2023.
Cassia Cearley Insider Trading History at Icosavax
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Icosavax Company Overview
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.